Salta al contenuto principale
Passa alla visualizzazione normale.

ANTONIO GALVANO

Pubblicazioni

Data Titolo Tipologia Scheda
2023 Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Articolo in rivista Vai
2023 Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay Articolo in rivista Vai
2023 Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab Articolo in rivista Vai
2023 Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis Review essay (rassegna critica) Vai
2023 The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors Articolo in rivista Vai
2023 The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? Articolo in rivista Vai
2023 Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) Articolo in rivista Vai
2023 KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study Articolo in rivista Vai
2023 Network approach in liquidomics landscape Articolo in rivista Vai
2022 Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible Articolo in rivista Vai
2022 Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis Articolo in rivista Vai
2022 Molecular tumor board Capitolo o Saggio Vai
2022 Current clinically validated applications of liquid biopsy Capitolo o Saggio Vai
2022 Future perspectives Capitolo o Saggio Vai
2022 Liquid biopsy and immunotherapy: is all that glitter gold? Capitolo o Saggio Vai
2022 Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors Articolo in rivista Vai
2022 Early detection screening: myth or reality? Capitolo o Saggio Vai
2022 Liquid biopsy: a right tool in a right context? Capitolo o Saggio Vai
2022 Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis Articolo in rivista Vai
2022 PROTACs: The Future of Leukemia Therapeutics Articolo in rivista Vai
2022 Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study Articolo in rivista Vai
2022 The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis Articolo in rivista Vai
2022 Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare Lettera Vai
2022 Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. Articolo in rivista Vai
2022 Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement Articolo in rivista Vai
2021 Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma Recensione in rivista Vai
2021 Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups Articolo in rivista Vai
2021 Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study Articolo in rivista Vai
2021 The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies Articolo in rivista Vai
2021 Second medical opinion in oncological setting Articolo in rivista Vai
2021 Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer Articolo in rivista Vai
2021 The treatment of medication-related osteonecrosis of the jaw (Mronj): A systematic review with a pooled analysis of only surgery versus combined protocols Review essay (rassegna critica) Vai
2021 The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials Articolo in rivista Vai
2021 Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) Articolo in rivista Vai
2021 Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses Articolo in rivista Vai
2021 A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic Articolo in rivista Vai
2020 Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis Articolo in rivista Vai
2020 Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score Articolo in rivista Vai
2020 2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials Lettera Vai
2020 COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? Articolo in rivista Vai
2020 Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab Articolo in rivista Vai
2020 The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer Review essay (rassegna critica) Vai
2020 The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal Articolo in rivista Vai
2020 Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study Articolo in rivista Vai
2020 Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer Articolo in rivista Vai
2019 Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients Articolo in rivista Vai
2019 An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy Articolo in rivista Vai
2019 How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis Articolo in rivista Vai
2019 Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials Articolo in rivista Vai
2019 Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis Articolo in rivista Vai
2019 How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials Articolo in rivista Vai
2019 Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 Articolo in rivista Vai
2019 Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Review essay (rassegna critica) Vai
2018 Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis Articolo in rivista Vai
2018 Indications for locoregional tumor therapies: CRC liver metastases Capitolo o Saggio Vai
2018 Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) Nota o commento Vai
2018 Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study Articolo in rivista Vai
2018 The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis Articolo in rivista Vai
2018 Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer Articolo in rivista Vai
2018 The use of same in chemotherapy-induced liver injury Articolo in rivista Vai
2018 Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer Articolo in rivista Vai
2018 Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential Articolo in rivista Vai
2018 Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab Articolo in rivista Vai
2018 Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Articolo in rivista Vai
2017 Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma Abstract in atti di convegno pubblicato in rivista Vai
2017 Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study Articolo in rivista Vai
2017 The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials Articolo in rivista Vai
2017 Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy Articolo in rivista Vai
2017 Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin Abstract in atti di convegno pubblicato in rivista Vai
2017 Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin Articolo in rivista Vai
2017 "Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors Articolo in rivista Vai
2016 Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway Review essay (rassegna critica) Vai
2016 Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? Articolo in rivista Vai
2016 Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis Articolo in rivista Vai
2016 Dietary restriction: could it be considered as speed bump on tumor progression road? Articolo in rivista Vai
2016 Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors Capitolo o Saggio Vai
2016 Nintedanib in NSCLC: Evidence to date and place in therapy Articolo in rivista Vai
2016 PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis Articolo in rivista Vai
2016 Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus Articolo in rivista Vai
2016 The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? Articolo in rivista Vai
2015 Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy Articolo in rivista Vai
2015 New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? Articolo in rivista Vai
2015 Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials Articolo in rivista Vai
2015 Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis Articolo in rivista Vai
2015 Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario Articolo in rivista Vai
2014 Ramucirumab and its use in gastric cancer treatment Articolo in rivista Vai
2013 Monoclonal antibodies in gastrointestinal cancers Articolo in rivista Vai
2013 Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations Articolo in rivista Vai
2010 The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results eedings Vai
2010 Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety eedings Vai